Mutations within members of the EGF/ErbB receptor family frequently release the oncogenic potential of these receptors, resulting in the activation of downstream signaling events independent of ligand regulatory constraints. We previously have demonstrated that the signal transduction events originating from S3-v-ErbB, a ligandindependent, oncogenic EGF receptor mutant, are qualitatively distinct from the ligand-dependent mitogenic signaling pathways associated with the wild-type EGF receptor. Specifically, expression of S3-v-ErbB in primary fibroblasts results in anchorage-independent growth, increased invasive potential, and the formation of a transformation-specific phosphoprotein signaling complex, all in a Ras-independent manner. Here we demonstrate the transformation-specific interaction between two components of this complex: the adaptor protein Grb2 and the cytoskeletal regulatory protein caldesmon. This interaction is mediated via both the amino-terminal SH3 and central SH2 domains of Grb2, and the aminoterminal (myosin-binding) domain of caldesmon. Expression of a dominant-negative Grb2 deletion mutant, which lacks the carboxy-terminal SH3 domain, in fibroblasts expressing S3-v-ErbB results in a reduction in phosphoprotein complex formation, the loss of anchorageindependent growth, and a reduction in invasive potential.
Introduction
In tumors originating from a diverse spectrum of tissues, the EGF/ErbB receptor gene has been shown to be the target of selected mutations (Salomon et al. , 1995; Klapper et al., 2000) . These mutations frequently result in the expression of EGF/ErbB receptor mutants that are constitutively kinase active, and that dimerize in the absence of ligand binding (reviewed in Boerner et al., 2003) . While such mutations render these receptors constitutively active (Nair et al., 1993; Huang et al., 1997) , we and others have been able to dissociate both kinase activation and dimerization from oncogenic signaling (Nair et al., 1993; Adelsman et al., 1996; Penington et al., 2002) . Specifically, we have shown that deletion of the ligand-binding domain of the avian EGF receptor (i.e. E1-v-ErbB) results in both elevated kinase activity and constitutive cell surface dimerization of the receptor in primary fibroblasts, but that this receptor mutant is not sarcomagenic. In contrast, another ligandindependent avian viral mutant of the EGFR, that is, S3-v-ErbB, induces the rapid formation of highly vascularized fibrosarcomas and hemangiosarcomas in vivo (Maihle et al., 1988; Raines et al., 1988a,b) . Relative to the EGF receptor, S3-v-ErbB has sustained a truncation of the extracellular ligand-binding domain, as well as an in-frame deletion of 139 amino acids within the carboxy-terminal regulatory domain (Raines et al., 1988a,b) . These studies suggest that constitutive kinase activation and receptor dimerization must occur in the context of a specific cellular environment for malignant transformation to occur.
This specificity of transformation suggests that the substrates downstream of the receptor tyrosine kinase are tissue-specific (reviewed in Maihle and Kung, 1989) . In addition to being tissue-specific, recent studies in our laboratory further suggest that these ligand-independent oncogenic signaling events are distinct from their liganddependent mitogenic counterparts, and in fact are often unique to tumor cells, thereby potentially providing new targets for the development of highly selective anticancer therapeutics.
Infection of primary fibroblasts with a retroviral vector containing S3-v-ErbB results in anchorageindependent growth, increased invasive potential, loss of actin-based stress fibers, and the formation of a transformation-specific, tyrosine phosphoprotein complex (hereafter referred to as the phosphoprotein complex) (McManus et al., 1995; . This phosphoprotein complex includes the adapter proteins Shc and Grb2, as well as the cytoskeletal regulatory proteins Pak and caldesmon (McManus et al., 1995 Wang et al., 1999) .
During normal, ligand-dependent signaling by the EGF receptor, Grb2 transmits an activation signal to the mitogenic Ras protein by binding simultaneously to receptor-bound Shc (via the SH2 domain of Grb2) and (via the amino-terminal SH3 domain of Grb2) to the nucleotide exchange factor Sos (Lowenstein et al., 1992; Chardin et al., 1993; Gale et al., 1993; Li et al., 1993) . Thus, the presence of both Shc and Grb2 in this phosphoprotein complex initially implied a role for Ras signaling during the process of S3-v-ErbB-mediated transformation. Subsequent studies utilizing the N17Ras dominant-negative mutant revealed that not only is cell transformation by S3-v-ErbB independent of Ras activation, but that S3-v-ErbB expression actually results in downregulation of ligand-stimulated Ras activity (Bell et al., 1993; Boerner et al., 2000) . Together, these results suggest alternative function(s) for Grb2 as well as for Shc activity during the process of S3-v-ErbBinduced oncogenic transformation.
Here we report that in primary fibroblasts transformed by S3-v-ErbB, Grb2 interacts with caldesmon, an actin-/myosin-binding protein, through both the amino-terminal SH3 and central SH2 domains of Grb2. While caldesmon expression has previously been reported to be altered (usually reduced) in a variety of human cancers (Owada et al., 1984; Tanaka et al., 1993; Yamashiro et al., 1994) , to date no mechanistic studies defining a specific role for caldesmon in the process of malignant transformation have been reported. Here, we demonstrate that tyrosine phosphorylation of the amino-terminal region of caldesmon disrupts this caldesmon : actin interaction. Moreover, we show that this tyrosine-phosphorylated form of caldesmon specifically interacts with Grb2, and that caldesmon binding to a dominant-negative Grb2 mutant has the ability to block anchorage-independent growth and also to suppress the invasive capacity of S3-v-ErbB-expressing cells. These studies demonstrate an essential role for Grb2 in the process of oncogenic signaling by the EGF receptor, and implicate binding to the tyrosine-phosphorylated form of caldesmon in this process.
Results

Oncogenic EGF receptor mutant induces formation of a tyrosine phosphoprotein complex in primary fibroblasts
Chick embryo fibroblasts (CEF) were isolated from day 9 embryos and infected with a helper-independent retroviral vector containing the S3-v-erbB oncogene (Hughes and Kosik, 1984) . Lysates from CEF, or CEF transformed by S3-v-ErbB retroviral infection (CEFS3), were immunoprecipitated with an antibody to Shc and immunoblotted with an antibody to phosphotyrosine. While no detectable bands are present in the CEF lane, the CEFS3 lane shows a broad band of tyrosinephosphorylated proteins (Figure 1a ). Here we report that microsequence analysis revealed the p55 and p52 bands to represent two isoforms of the adaptor protein Shc, while previously the adaptor protein Grb2 (McManus et al., 1995) and the cytoskeletal regulatory protein caldesmon were identified as proteins within this phosphoprotein complex. While Grb2 is not tyrosine phosphorylated in this phosphoprotein complex (data not shown), Figure 1b shows that caldesmon is tyrosine phosphorylated only in cells expressing S3-v-ErbB.
Grb2 interacts with caldesmon in S3-v-ErbB-transformed fibroblasts
Since caldesmon becomes tyrosine phosphorylated during formation of this complex (Figure 1b) , we speculated that caldesmon might be interacting with the SH2 domains of either Grb2 or Shc, or both. To test this hypothesis, we relied on the fact that caldesmon is a heat-stable protein, tolerating temperatures of 1001C for 10 min with no loss of function (Marston and Redwood, 1991) or tyrosine phosphorylation (Z Wang, unpublished data). Thus, cell lysates were heat treated prior to use to disrupt interactions between caldesmon and endogenous binding partners to ensure that any interaction observed would be the result of direct binding of caldesmon with fusion protein. Heat-treated lysates from CEFS3 were used in Gst-pulldown assays. The Figure 1 Formation of a phosphoprotein complex and tyrosine phosphorylation of caldesmon in S3-v-ErbB-infected CEF. (a) Cell lysates from CEF or CEF infected with S3-v-ErbB were immunoprecipitated with a polyclonal antibody to Shc, subjected to 8% SDS-PAGE, and immunoblotted with a monoclonal antibody to phosphotyrosine. Microsequence analysis revealed the two lower bands to be the p55 and p52 isoforms of Shc. (b) Cell lysates from CEF and S3-v-ErbB-transformed CEF were immunoprecipitated with a monoclonal antibody to caldesmon, fractionated by SDS-PAGE, and immunoblotted with a monoclonal antibody to phosphotyrosine. An equal loading control was performed by immunoblotting 100 mg of cell lysate with a monoclonal antibody to caldesmon results presented in Figure 2 suggest that caldesmon directly interacts with Gst-Grb2, and not with either Gst alone or with Gst-Shc in CEFS3; however, while we interpret this interaction to be direct, it is possible that the binding of Grb2 to caldesmon involves intervening (also heat stable) protein(s).
To confirm the observed biochemical interaction between Grb2 and caldesmon, we performed double immunofluorescence localization studies. CEF (Figure 3a) , and CEFS3 ( Figure 3b ) were labeled with primary (and corresponding fluorochrome-labeled secondary) antibodies to caldesmon (green) and Grb2 (red). The localization of these proteins was observed by confocal microscopy. In these studies, the majority of CEF cells displayed a uniform pattern of Grb2 distribution throughout the cytoplasm, while caldesmon was localized in a characteristic periodic pattern along actin microfilaments (Figure 3a , and data not shown) (Tanaka et al., 1993; Goncharova et al., 2001) . In contrast, CEFS3, which we have previously shown to have a reduced number of actin microfilaments (McManus et al., 1995; Boerner et al., 2000 Boerner et al., , 2001 , display a diffuse pattern of caldesmon localization (Figure 3b ). In addition, CEFS3 display overlapping areas of caldesmon and Grb2 aggregation in cell protrusions at the leading edge of the cell (Figure 3b) . Thus, an apparent interaction between Grb2 and caldesmon can be observed only in CEFS3, as shown here by both Gst-pulldown assays in vitro and by immunofluorescence in CEFS3 in vivo.
Grb2 interacts with caldesmon through the aminoterminal SH3 and central SH2 domains of Grb2
To determine which domains of Grb2 interact with caldesmon, we utilized Gst-Grb2 fusion proteins consisting of each of the three individual domains of Grb2 (Figure 4a ). Heat-treated cell lysates from CEFS3 were incubated with Gst-fusion proteins comprised of either full-length Grb2, or its amino-terminal SH3 domain, central SH2 domain, or carboxy-terminal SH3 domain. Figure 4b shows that caldesmon directly associates with both the amino-terminal SH3 and central SH2 domains of Grb2, but not with the carboxy-terminal SH3 domain of Grb2. These results were confirmed and extended using site-directed mutants of caldesmon, which individually lack each of the three previously characterized phosphotyrosine acceptor sites of caldesmon (i.e. tyrosines 27, 165, and 363) (Wang et al., 1999) . Figure 5 illustrates that only phosphotyrosine-27 of caldesmon is required for binding to either the aminoterminal SH3 or central SH2 domains of Grb2.
Expression of a Grb2 mutant lacking the carboxyterminal SH3 domain disrupts phosphoprotein complex formation in S3-v-ErbB-transformed CEF
To test if the expression of a carboxy-terminal SH3 domain deletion mutant of Grb2 might act as a dominant negative, we coinfected CEF with two empty retroviral vectors (one with envelope subtype A, the other with envelope subtype B) ( 
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caldesmon Figure 2 Analysis of protein-protein interactions in S3-v-ErbBinfected CEF. Gst, Gst-Shc, and Gst-Grb2-fusion proteins were produced and purified as described in Experimental procedures. Equal amounts of Gst, Gst-Shc, or Gst-Grb2 (1 mm) immobilized on glutathione-agarose beads were incubated with 500 mg of heattreated (Gst, Gst-Shc, Gst-Grb2) lysate from S3-v-ErbB-transformed CEF. Gst-fusion protein complexes were subjected to SDS-PAGE and immunoblotted with a monoclonal antibody to caldesmon. Equal amounts of fusion protein were isolated, as detected by GST immunoblots Figure 3 Visualization of the Grb2 : caldesmon interaction in S3-v-ErbB-transformed CEF. (a) CEF and (b) CEF transformed by S3-v-ErbB were grown on glass coverslips for 48 h at 371C in complete culture media. Cells were fixed by treatment with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. The fixed cells were incubated with a polyclonal antibody to Grb2 (red) and a monoclonal antibody to caldesmon (green) for 1 h at room temperature. Cells were visualized by confocal microscopy with a Â 100 objective and the cells imaged represent greater than 50% of the cells observed expression of S3-v-ErbB in CEF lysate from these infected cells. Both the myc-tagged wild-type Grb2 and the carboxy-terminal SH3 domain deletion mutant appear to be stable, with levels of expression well above those of endogenous Grb2 (Figure 6a ). After verification of S3-v-ErbB and Grb2 expression levels, equal amounts of cell lysates from samples of coinfected CEF were immunoprecipitated with an antibody to SHC, followed by immunoblot analysis with an antibody to phosphotyrosine to assay for phosphoprotein complex formation. Figure 6b shows that while the levels of tyrosine-phosphorylated p52 and p55 Shc remain relatively constant in all CEFS3, CEF expressing the carboxy-terminal SH3 domain deletion mutant (DC-Grb2) show a dramatic reduction in the level of phosphoproteins within this multiprotein complex 
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Figure 4 Characterization of the interaction between Grb2 and caldesmon in S3-v-ErbB-transformed CEF. (a) Structural domains of wild-type Grb2 and a carboxy-terminal SH3 domain mutant. An illustration of the structural domains and organization of wild-type Grb2 and a carboxy-terminal SH3 domain mutant used in this study. (b) Gst, Gst-Grb2, Gst-Grb2-amino-terminal SH3, Gst-Grb2-SH2, and the Gst-Grb2-carboxy-terminal SH3 fusion proteins were produced and purified as described in Experimental procedures. Equal amounts of heat-treated lysate (500 mg) from S3-v-ErbB-transformed CEF were incubated at 41C with 1 mm of each Gst construct immobilized on glutathione-agarose beads. Gst-protein complexes were subjected to SDS-PAGE and immunoblotted with a monoclonal antibody to caldesmon. Equal protein concentrations were established by fractionating 100 mg of lysate with SDS-PAGE and immunoblotting with a monoclonal antibody to caldesmon. This is a representative immunoblot of three experiments Figure 5 Characterization of differential Grb2-binding properties of caldesmon tyrosine-to-phenylalanine mutants. Immortalized CEF (DF-1), which do not express detectable levels of endogenous caldesmon, were infected with a retroviral vector containing S3-vErbB and transfected with expression vectors containing mutants of caldesmon in which one of three tyrosine residues was replaced with phenylalanine (Y27F, Y165F, or Y393F). Equal amounts (500 mg) of heat-treated lysate from each of the transfectants was incubated at 41C with 1 mm of either Gst (Gst), Gst-Grb2 (Grb2), Gst-Grb2 amino-terminal SH3 domain (N-SH3), Gst-Grb2 central SH2 domain (SH2), or Gst-Grb2 carboxy-terminal SH3 domain (C-SH3). The Gst-protein complexes were subjected to SDS-PAGE and immunoblotted with a monoclonal antibody to caldesmon. Equal protein concentrations were established by fractionating 100 mg of lysate from each transfectant with SDS-PAGE and immunoblotting with a monoclonal antibody to caldesmon. This is a representative immunoblot of three experiments ( Figure 6b ). This reduction in the phosphoprotein complex suggested that this Grb2 deletion mutant might also disrupt other hallmarks of S3-v-ErbB-mediated transformation.
Expression of DC-Grb2 decreases tyrosinephosphorylated levels of caldesmon and restores caldesmon-actin interactions
To determine whether expression of this DC-Grb2 mutant reduced phosphoprotein complex formation by inhibiting the tyrosine phosphorylation of individual complex components and/or by preventing the association of tyrosine-phosphorylated proteins with Shc, we directly immunoprecipitated caldesmon from CEFS3 which were coexpressing the DC-Grb2 mutant, and then immunoblotted with an antibody to phosphotyrosine. As observed in Figure 1 , in CEFS3, tyrosine-phosphorylated caldesmon migrates as a blurry band at B75 Kda; in nontransformed CEF (Figure 7a , CEF) or in CEFS3 that are coexpressing the carboxy-terminal SH3 domain Grb2 mutant (Figure7a, DC/S3), no tyrosine phosphorylation of caldesmon can be detected. Therefore, expression of the DC-Grb2 mutant in CEFS3 appears to inhibit directly the tyrosine phosphorylation of caldesmon. Previous reports have demonstrated that the ability of caldesmon to bind to, and thereby stabilize, actin microfilaments is antagonized by the cell cycle-dependent phosphorylation of caldesmon on select serine and threonine residues by the cdc2 kinase (Matsumura and Yamashiro, 1993; Yamashiro et al., 1994) . We therefore hypothesized that the tyrosine phosphorylation of caldesmon in transformed fibroblasts might also prevent caldesmon from associating with actin. To test this hypothesis, we immunoprecipitated caldesmon from CEF, CEFS3, Wt-Grb2/S3, or DC-Grb2/S3 cell lysates and immunoblotted for actin. Figure 7b demonstrates that while caldesmon coprecipitates with actin in CEF, in CEFS3 (in which caldesmon is tyrosine phosphorylated) there is a reduction in the level of co-precipitation of caldesmon with actin. Furthermore, expression of the DCGrb2 mutant (which inhibits caldesmon tyrosine phosphorylation) in CEFS3 restores the ability of caldesmon to co-precipitate with actin ( Figure 7b) . It therefore appears that the tyrosine phosphorylation of caldesmon results in its disassociation from actin, presumably contributing to the actin microfilament disassembly that is observed in S3-v-ErbB-transformed fibroblasts (McManus et al., 1995 Boerner et al., 2001) , and also perhaps to other biological end points highly correlated with the transformed phenotype, as described below. (DC/S3) were subjected to SDS-PAGE and immunoblotted with a polyclonal antibody to v-ErbB or a polyclonal antibody to Grb2. The S3-v-ErbB protein migrates as a broad band in the 60-68 kDa range as a result of extensive N-linked glycosylation during receptor maturation. The addition of the myc-tag to the wild-type Grb2 construct results in an upward shift in the migration of this protein. Likewise, the removal of the carboxy-terminal SH3 domain in the DC-mutant Grb2 construct results in a downward shift in protein migration. (b) Analysis of phosphoprotein complex formation. Equal amounts of cell lysate (500 mg) from the samples described in (a) were incubated with a polyclonal antibody to Shc at 41C overnight. Immune complexes were subjected to SDS-PAGE and immunoblotted with a monoclonal antibody to phosphotyrosine. Equal protein loading was confirmed by immunoblotting total cell lysate from the various samples with a polyclonal antibody to Shc. The major isoforms of Shc are indicated. This is a representative immunoblot of three experiments Oncogenic signaling by ligand-independent EGFR requires Grb2 JL Boerner et al Expression of DC-Grb2 results in the loss of anchorage-independent growth and increased invasive capacity of S3-v-ErbB-expressing fibroblasts Owing to the significant inhibitory effect of the DCGrb2 mutant on both formation of the transformationspecific phosphoprotein complex and the tyrosine phosphorylation of caldesmon, we investigated whether functional characteristics of cell transformation also could be inhibited by this Grb2 mutant. Soft agar colony assays were conducted by placing 5.0 Â 10 5 cells in 0.5% agar and incubating at 371C for 3 weeks; colonies were counted and colonies of greater than 50 cells were scored positive. Figure 8a shows that while coexpression of wild-type Grb2 (WT/S3) had little effect on the ability of S3-v-ErbB-infected cells to form colonies, coexpression of the carboxy-terminal SH3 domain deletion mutant of Grb2 (DC/S3) reduced the colony-forming ability of CEFS3. To assay for invasive potential, we performed motility assays using a modified Boyden's Chamber to measure the ability of cells to invade across a filter coated with extracellular matrix proteins (Albini et al., 1987) . Figure 8b demonstrates that coexpression of the carboxy-terminal SH3 domain deletion mutant of Grb2 in CEFS3 (DC/S3) results in the loss of invasive potential relative to either CEFS3 or to CEFS3 expressing wild-type Grb2 (WT/S3).
Discussion
The existence of signal transduction events unique to transformed cells has been sought as a means to develop , and CEF infected with S3-v-ErbB and DC-mutant Grb2 (DC/S3) were incubated with a monoclonal antibody to caldesmon at 41C overnight. Immune complexes were subjected to SDS-PAGE and immunoblotted with a monoclonal antibody to phosphotyrosine residues. Equal protein loading was ensured by subjecting 100 mg of total cell lysate to SDS-PAGE and immunoblotting with a monoclonal antibody to caldesmon. (b) Equal amounts (500 mg) of lysates from CEF cells infected as in (a) were incubated with a monoclonal antibody to caldesmon at 41C overnight. Immune complexes were subjected to SDS-PAGE and immunoblotted with a polyclonal antibody to actin. Equal protein concentrations were confirmed by subjecting 100 mg of total cell lysate to SDS-PAGE and immunoblotting with a polyclonal antibody to actin. This is a representative immunoblot of three experiments Figure 8 Functional analysis of the effect of wild-type and DCmutant Grb2 overexpression on S3-v-ErbB-mediated transformation. (a) Analysis of anchorage-independent growth. An equal number (500 000) of CEF infected with RCAN (A) only and RCAS (B) only (CEF), CEF infected with S3-v-ErbB and RCAS (B) only (S3), CEF infected with S3-v-ErbB and wild-type Grb2 (WT/S3), and CEF infected with S3-v-ErbB and DC-mutant Grb2 (DC/S3) was plated in 0.5% agarose supplemented with culture media and incubated at 371C. Colonies (450 cells) were counted at 3 weeks. Soft agar assays were performed in triplicate, and the standard error was calculated. (b) Analysis of invasive capacity. An equal number (20 000) of CEF cells infected as in (a) was suspended in serum-free culture media and seeded onto coated filters in a modified Boyden's Chamber with 5% FBS containing culture media acting as the chemoattractant. After 22 h at 371C, the filters were fixed, and the cells that had invaded to the lower surface of the filters were counted. Invasion assays were performed in triplicate, and the standard error was calculated based on these values tumor cell-specific targeted therapeutics. In this report, we have characterized a tyrosine phosphoprotein complex that forms only in cells transformed by S3-v-ErbB, thereby identifying the constituents of this complex as potential targets for the development of novel chemotherapeutics. This phosphoprotein complex includes a tyrosine-phosphorylated form of the actin cytoskeletal regulatory protein caldesmon, as well as the adaptor protein Grb2. Here we demonstrate a novel, Rasindependent, cytoskeletal function for Grb2 during vErbB-mediated oncogenesis, that is, the regulation of anchorage-independent growth and cell motility through an apparent direct association with caldesmon.
Grb2 and caldesmon interactions in transformed fibroblasts
We have previously shown that transformation by S3-vErbB involves the tyrosine phosphorylation of several novel cytoplasmic targets, and is not simply the amplification of well-characterized mitogenic signaling events (McManus et al., 1995 Wang et al., 1999; Boerner et al., 2000 Boerner et al., , 2001 . In this report, we demonstrate that Grb2 plays a central role in modulating the integrity of the actin-based cytoskeleton during ligand-independent S3-v-ErbB-mediated transformation. Based on these observations, we propose that the interaction between Grb2 and tyrosine-phosphorylated caldesmon results in the release of caldesmon from actin-based stress fibers and subsequent redistribution of caldesmon to the cell periphery. This redistribution of caldesmon could be one mechanism for the observed loss of stress fibers in transformed fibroblasts (McManus et al., 1995 . Previously, we have shown that another cytoskeletal regulatory protein, the serine kinase Pak is also a member of this tyrosine phosphoprotein complex.
Interestingly, Pak has also been recently shown to bind directly to Grb2 via one of Grb2's SH3 domains (Puto et al., 2003) . Tyrosine phosphorylation enhances Pak activity toward myosin light chain kinase , and this activity may further potentiate stress fiber disassembly, especially in combination with the effect of tyrosine phosphorylation of caldesmon Wang et al., 1999) . This unusual activation of Pak kinase activity by tyrosine phosphorylation has recently been referred to as superactivation (Renkema et al., 2002) , and also appears to occur downstream of cytoplasmic kinases such as Src, further implicating these regulatory proteins in oncogenic signal transduction.
Tyrosine phosphorylation of caldesmon appears to functionally mimic inhibitory cell cycle-dependent serine and threonine phosphorylation
We have previously reported the tyrosine phosphorylation of caldesmon and the correlation of this phosphorylation event with transformation (McManus et al., 1995 Wang et al., 1999) . Here we show that the tyrosine phosphorylation of caldesmon in S3-v-ErbBtransformed fibroblasts is somehow mediated by its interactions with Grb2, and that this phosphorylation event is correlated with a decrease in actin binding, anchorage-independent growth, and increased cell motility. Prior to this report, only serine/threonine phosphorylation of caldesmon by either the cdc2 kinase or Pak had been shown to release caldesmon from actin microfilaments, thereby promoting cytoskeletal reorganization in a cell cycle-dependent manner (Matsumura and Yamashiro, 1993; Yamashiro et al., 1994) . Here we show that tyrosine phosphorylation of caldesmon during S3-v-ErbB-mediated transformation may function in a similar manner as cdc2 serine/threonine phosphorylated caldesmon, that is, by promoting caldesmon disassociation from actin. Figure 9 describes one interpretation of the observed interactions between Grb2 and tyrosine-phosphorylated caldesmon. Together, our observations suggest that a weak interaction occurs between Grb2 and caldesmon (in normal and transformed cells), and that this interaction is mediated by the N-terminal SH3 domain of Grb2 and the Cterminus of caldesmon. In transformed cells, an unknown tyrosine kinase downstream of oncogenic vErbB mutants phosphorylates caldesmon primarily on residues Tyr-27 and Tyr-393 (Wang et al., 1999) , thereby enhancing the interaction between Grb2 and caldesmon, as illustrated in Figures 5 and 9 . Since Tyr-27 appears to coordinate the binding of caldesmon to both the aminoterminal SH3 and central SH2 domains of Grb2, in the simplest model, tyrosine phosphorylation of caldesmon may result in the preferential binding of Grb2 to caldesmon, thereby disrupting the binding of caldesmon to mirofilaments. These tyrosines are located well within the myosin-and actomyosin-binding domains of caldesmon (Matsumura and Yamashiro, 1993) . In this manner, the tyrosine phosphorylation of caldesmon in transformed cells, perhaps similar to serine and threonine phosphorylation of caldesmon during the normal cell cycle, results in the release of caldesmon from the actin cytoskeleton.
In any event, the removal of the inhibitory effect of caldesmon on cytoskeletal reorganization appears to be one critical aspect of ligand-independent oncogenic signaling by the EGF receptor. Indeed, caldesmon expression has previously been shown to be downregulated in transformed cells (Owada et al., 1984; Tanaka et al., 1993; Yamashiro et al., 1994) . It may be that the constitutive tyrosine phosphorylation of caldesmon during S3-v-ErbB cell transformation phenocopies the downregulation of caldesmon expression observed in certain human tumors and tumor-derived cell lines (Owada et al., 1984; Tanaka et al., 1993) . Clearly, caldesmon warrants further study as a potential mediator of the biological consequences of oncogenic signaling by other oncogenes, especially other tyrosine kinases.
Disruption of transformation through deletion of the carboxy-terminal SH3 domain of Grb2
The primary function of Grb2 is to facilitate proteinprotein interactions via the two terminal SH3 domains and the central SH2 domain. The ability of Grb2 to bind to several proteins through these domains gives Grb2 a 'modular' function in assembling multiprotein signaling complexes Rozakis-Adcock et al., 1993) . Here we show a role for Grb2 in the formation of a putative 'transformation module' by binding to and promoting the tyrosine phosphorylation of caldesmon. However, whether the Grb2 interactions with tyrosinephosphorylated caldesmon, as observed in this study, occur during any normal cell processes or are transformation-specific, as suggested here, will require further study.
Several reports have demonstrated that Grb2 expression is correlated with oncogenic signaling in vitro and in vivo (Daly et al., 1994; Cheng et al., 1998; Tari et al., 1999) . While early reports of Grb2 involvement in transformation focused solely on its role in activating the Ras oncogene, several recent papers have also investigated the role of Grb2 in modulating the cytoskeleton during transformation (Xie et al., 1995; Cheng et al., 1998; Gay et al., 1999; Dankort et al., 2001a, b; Saucier et al., 2002) . In agreement with this report, several of these studies have demonstrated the ability of various Grb2 domain mutants to reverse the transformed phenotype (Xie et al., 1995; D'Ambrosio et al., 1996; Cheng et al., 1998) . Our results provide a possible mechanistic explanation for the observed dominant-negative activity of the Grb2 carboxy-terminal SH3 domain mutant in these other studies, that is, a failure to link caldesmon to unknown protein(s) thereby restoring the integrity of the actin-based cytoskeleton. Further work in this area will be required to determine the identity of these putative Grb2-binding partner(s), and how these protein interactions may contribute to the complex process of transformation.
Experimental procedures
Cells and viruses
Primary CEF (line f) and immortalized CEF (DF-1) were cultured in Dulbecco's modified Eagle's medium (DMEM), with 10% fetal bovine serum and 2% chick serum at 371C. The helper-independent retroviral vectors RCAN and RCAS were used for all infections and transfections (Hughes and Kosik, 1984) .
Grb2 and caldesmon constructs
The wild-type and DC Grb2 cDNA constructs were gifts from Dr AM Prendergast. The full-length Grb2 cDNA inserted into the pGEX-3x vector was provided by Dr P Findell (Syntex Research). The cDNAs encoding the Figure 9 Model summarizing the proposed interaction sites between tyrosine-phosphorylated caldesmon and Grb2. Previous results have shown the presence of a weak interaction between caldesmon and Grb2 in normal fibroblasts . This weak interaction appears to be mediated by the N-terminal SH3 domain of Grb2 and a proline-rich sequence located in the C-terminal region of caldesmon. Oncogenic transformation results in the tyrosine phosphorylation of caldesmon, among other proteins (Figure 1) . We propose that this tyrosine phosphorylation of caldesmon produces a structural change in the molecule, resulting not only in enhanced binding of caldesmon to Grb2, but also in the decreased ability of caldesmon to bind to and stabilize actin microfilaments (Figure 7 ). This 'strong binding' results from the ability of Grb2 to perhaps more efficiently bind caldesmon via its N-terminal SH3 domain, and additionally to now interact with the tyrosine-phosphorylated caldesmon through its central SH2 domain. The caldesmon tyrosine residue principally responsible for mediating this interaction appears to be Tyr-27. Interestingly, this residue lies within the myosin-binding domain of caldesmon amino-terminal SH3 domain (residues 1-57), SH2 domain (residues 58-160), and carboxy-terminal SH3 domain (residues 161-217) of Grb2 within the pGEX-3x vector were gifts from Dr T Pawson. The Myc-tag was added to the wild-type Grb2 cDNA by PCR with the primers:
PCR was performed in a 100 ml reaction mixture containing 2.5 U of Taq DNA polymerase (Stratagene), 400 ng of each primer, 0.4 mm dNTPs, and 500 ng of template. The reaction parameters were 941C for 1 min, 551C for 2 min, and 741C for 2 min, for a total of 30 cycles. The PCR product was digested with BamHI (New England Biolabs) and cloned into the RCAS envelope subtype (B) retroviral vector.
The caldesmon tyrosine-to-phenylalanine mutants were constructed using the Stratagene Quik Change site-directed mutagenesis kit according to the manufacturer's instructions. The oligonucleotides utilized to construct the relevant mutants were as follows:
Retroviral coinfection
Low-passage CEF were infected with the RCAS (envelope subtype B) retrovirus containing the relevant Grb2 construct or no insert (CEF) for 3 days. At 1 week postinfection, CEF were coinfected with the RCAN (envelope type A) retrovirus containing S3-v-ErbB or no insert (CEF) in the presence of 2 mg polybrene for 4 days, as described previously (Aftab et al., 1997) .
Cell lysis, immunoprecipitation, and immunoblotting
Cell lysis was performed as previously described (McManus et al., 1995; Wang et al., 1999) . Briefly, cells were harvested in a lysis buffer containing 1% Triton X-100, 50 mm HEPES, pH 7.5, 1% Nonidet P-40, 5 mm EDTA, 50 mm NaCl, 10 mm NaPP I , 0.5% deoxycholate, 100 mm vanadate, 4 mm DFP, 1 mm PMSF, 10 mg/ml pepstatin A, and 10 mg/ml leupeptin. Protein concentration was determined by the Lowry method using the DC Protein Assay Kit from BioRad. Aliquots of lysate containing equal amounts of protein were subjected to 10% SDS-PAGE. Immunoblotting was carried out as described previously (McManus et al., 1995; Wang et al., 1999) . For immunoprecipitation assays, 500 mg of cell lysate was incubated with the appropriate antibody overnight at 41C with gentle rocking. Protein A/G beads (35 ml) (Pierce, Rockford, IL, USA) were then added, and the samples rocked for 30 min at 41C. The immune complexes were washed 3 Â in immunoprecipitation buffer B (150 mm NaCl, 10 mm Tris-HCl (pH 9.0), 5 mm EDTA, 0.1% Triton X-100) and 3 Â in Tris-buffered saline (10 mm Tris-HCl (pH 7.4), 150 mm NaCl), followed by SDS-PAGE. Proteins were transferred to PVDF membrane followed by immunoblot analysis.
Gst-pulldown assays
Gst-fusion constructs or Gst-only vectors were transformed into DH5a E. coli. Cultures were grown to an optical density of 0.4-0.5 at 600 nm. Gst-fusion proteins were generated by induction with 1 mm IPTG (Sigma) for 4 h at 371C. Gst-fusion proteins were purified using glutathione-agarose beads according to the manufacturer's protocol (Pierce, Rockford, IL, USA). Purified fusion proteins were subjected to SDS-PAGE, stained with Coomassie Blue, and protein concentrations were quantitatively measured. Pulldown assays were performed by incubating 500 mg of cell lysate with 1 mm of Gst or a Gst-Grb2 fusion protein immobilized on glutathione-agarose beads in immunoprecipitation buffer A (190 mm NaCl, 50 mm Tris-HCl, pH 7.4, 6 mm EDTA, 2.5% Triton X-100) overnight at 41C. Beads were washed 3 Â with TBS, and then boiled for 4 min in SDS sample buffer (62.5 mm Tris-HCl (pH 6.8), 20% SDS, 1 mm EDTA, 10% glycerol, 5 mm DTT, and 0.45 mm bromophenol blue). Supernatants were resolved by SDS-PAGE (8% polyacrylamide), followed by transfer to PVDF for immunoblot analysis (see figure legends).
Soft agar colony assays
Retrovirally infected or uninfected CEF (line f) were plated as previously described (Connolly et al., 1994) . Plates were supplemented with a few drops of complete medium every 3 days, for a total of 3 weeks. Colonies (450 cells/colony) were counted by light microscopy. Soft agar assays were performed in triplicate.
Immunofluorescence
A total of 5 Â 10 3 cells were plated on 12 mm glass coverslips in regular growth media and grown overnight at 371C. Cells were then fixed in 4% paraformaldehyde for 10 min, washed 3 Â with PBS, and permeabilized with 0.5% Triton X-100. Cells were washed 3 Â with PBS and incubated with blocking buffer (5% goat serum, 1% glycerol, 0.1% bovine serum albumin, and 0.1% gelatin in PBS) for 30 min at room temperature. Cells were then incubated with both Grb-2 rabbit polyclonal antibody (Santa Cruz c-23, sc-255) and caldesmon monoclonal antibody (Sigma c-0297) for 1 h at room temperature. Cells were washed 3 Â with PBS, and incubated with both FITC-conjugated antimouse and rhodamine-conjugated anti-rabbit antibodies (Caltag) for 1 h at room temperature. Cells were washed 3 Â with PBS, and mounted on glass slides with VectaSheild (Vector Labs). Images were captured using confocal microscopy with a Â 100 objective (Carl Zeiss, Model 5100).
Cell invasion assay
Cell invasion was assayed by a modified Boyden Chamber (Albini et al., 1987; Sato et al., 1994; Rochefort et al., 1998) according to the manufacturer's instructions (Becton Dickinson). Cells were suspended in serum-free DMEM and then seeded onto uncoated filters as control inserts (8-mm pore size) or onto Matrigel-coated filters (Bioboat Matrigel invasion chambers) in 24-well plates. Fetal calf serum (5%) in DMEM was used as a chemoattractant in the lower wells. After 22 h incubation, filters were fixed in cold methanol for 15 min and stained with hematoxylin. Cells that had invaded the lower surface of the filters were counted using light microscopy at a magnification of Â 400. Each assay was performed in triplicate. The invasion index was calculated as follows: % invasion test cells/% invasion control cells.
